Dossiers d'AMM à étudier par le Comité Technique des Spécialités Pharmaceutiques du 20/04/2023.
Pour ce comité technique, l’ordre de passage des dossiers sera comme suit .
Spécialités Pharmaceutiques fabriquées localement :
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | DATE Rapport |
1 | IRBEXTRA PLUS | IRBESARTAN/ HYDROCHLOROTHIAZIDE | 150 mg/12,5 mg | Comprimé pelliculé | B/30 | OPALIA PHARMA | E | N | 04/04/2023 |
2 | IRBEXTRA PLUS | IRBESARTAN/ HYDROCHLOROTHIAZIDE | 300 mg/25 mg | Comprimé pelliculé | B/30 | OPALIA PHARMA | E | N | 04/04/2023 |
3 | DEBRICOL | TRIMEBUTINE | 74,4 mg | Granulés pour suspension buvable | B/16 SACHETS | GALPHARMA | I | N | 04/12/2023 |
4 | MUCOLYSE | ACETYLCUSTEINE | 200 mg | Poudre pour solution orale | B/18 SACHETS | GALPHARMA | C | N | 04/12/2023 |
* Produits à évaluer pour la première fois au Comité Technique
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | DATE Rapport |
1 | BI-SPIRAZOL | SPIRAMYCINE + METRONIDAZOLE | 1,5 MUI/250 mg | Comprimé pelliculé | B/28 | ADWYA | E | N | 15/09/2022 |
2 | MEFOR | METFORMINE | 850 mg | Comprimé pelliculé | B/60 | TERIAK | E | V | 22/03/2023 |
3 | MEFOR | METFORMINE | 1000 mg | Comprimé pelliculé sécable | B/60 | TERIAK | E | V | 22/03/2023 |
4 | HCQ SAIPH | HYDROXYCHLOROQUINE SULFATE | 200 mg | Comprimé pelliculé | B/10 | SAIPH | E | N | 27/03/2023 |
5 | IPPEX | ESOMEPRAZOLE | 40 mg | Gélule | B/28 | ADWYA | E | N | 27/03/2023 |
6 | HCQ SAIPH | HYDROXYCHLOROQUINE SULFATE | 200 mg | Comprimé pelliculé | B/30 | SAIPH | E | N | 31/03/2023 |
7 | APRIVA | APREMILAST | 30 mg | Comprimé pelliculé | B/60 | IBN AL BAYTAR | I | N | 11/04/2023 |
8 | APRIVA | APREMILAST | 10mg/20mg/30mg | Comprimé pelliculé | B/28 | IBN AL BAYTAR | I | N | 11/04/2023 |
9 | CHLORURE DE SODIUM 0,9% | CHLORURE DE SODIUM | 0,90% | Solution injectable pour perfusion | P/100 ml | INFOMED | N | 11/04/2023 | |
10 | CHLORURE DE SODIUM 0,9% | CHLORURE DE SODIUM | 0,90% | Solution injectable pour perfusion | P/250 ml | INFOMED | N | 11/04/2023 | |
11 | CHLORURE DE SODIUM 0,9% | CHLORURE DE SODIUM | 0,90% | Solution injectable pour perfusion | P/1000 ml | INFOMED | N | 11/04/2023 | |
12 | IPROL | BROMURE D'IPRATROPIUM | 20 µg | Solution pour inhalation | FL/200 doses | BERG LIFE SCIENCE | E | N | 11/04/2023 |
13 | PLERIXAFOR NEAPOLIS | PLERIXAFOR | 20 mg/ml | Solution injectable | B/1FL/1,2ML | NEAPOLIS PHARMA | V | N | 11/04/2023 |
14 | RESPYVA | TIOTROPIUM | 18 µg | Poudre pour inhalation buccale | B/30 + INHALATEUR | NEAPOLIS PHARMA | E | N | 11/04/2023 |
15 | SUGAMMADEX MEDIS | SUGAMMADEX | 100 mg/ml | Solution injectable | B/10 FL/2ML | LES LABORATOIRES MEDIS | E | N | 11/04/2023 |
16 | SUGAMMADEX MEDIS | SUGAMMADEX | 100 mg/ml | Solution injectable | B/10 FL/5ML | LES LABORATOIRES MEDIS | E | N | 11/04/2023 |
17 | TACROLIMUS MEDIS | TACROLIMUS | 0,5 MG | Gélule | B/100 | LES LABORATOIRES MEDIS | V | N | 11/04/2023 |
18 | TACROLIMUS MEDIS | TACROLIMUS | 1 MG | Gélule | B/100 | LES LABORATOIRES MEDIS | V | V | 11/04/2023 |
19 | TACROLIMUS MEDIS | TACROLIMUS | 5 MG | Gélule | B/100 | LES LABORATOIRES MEDIS | V | V | 11/04/2023 |
Spécialités Pharmaceutiques importées
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | ZEFFIX | LAMIVUDINE | 100 MG | COMP PEL | B/28 | GSK IRELAND | E | T | 01/02/2023 |
2 | ARIXTRA | FONDAPARINUX SODIUM | 2.5mg/0.5ml (5mg/ml) | SOL INJ PR PERF | B/10 | ASPEN PHARMA TRADING Limited | N | 17/02/2023 | |
3 | ARIXTRA | FONDAPARINUX SODIUM | 7.5mg/0.6ml (12.5mg/ml) | SOL INJ PR PERF | B/10 | ASPEN PHARMA TRADING Limited | N | 17/02/2023 | |
4 | TRIMBOW | BECLOMETHASONE+FORMOTEROL+GLYCOPYRRONIUM | 87 µg/5 µg/9 µg | SOL PR INH | FL/120 | CHIESI FARMACEUTICI S.p.A | N | 17/02/2023 | |
5 | LISINOPRIL Atb | LISINOPRIL | 10mg | COMP | B/30 | ANTIBIOTICE S.A | E | N | 17/02/2023 |
6 | LISINOPRIL Atb | LISINOPRIL | 20mg | COMP | B/30 | ANTIBIOTICE S.A | E | N | 17/02/2023 |
7 | LISINOPRIL Atb | LISINOPRIL | 40mg | COMP | B/30 | ANTIBIOTICE S.A | E | N | 17/02/2023 |
8 | ENTEROGERMINA | SPORES DE BACILLUS CLAUSII POLYANTIBIO-RÉSISTANT | 4 milliards/5ml | SUSP BUV | B/10 | SANOFI-AVENTIS S.p.A | I | N | 20/02/2023 |
9 | ONCASPAR | PEGASPARGASE | 750 U/ML | PDRE PR SOL INJ | B/1 FL | SERVIER | E | N | 22/02/2023 |
10 | Jardiance | empagliflozine | 10 mg | comprimé | B/30 | Boehringer Ingelhei Allemagne | E | V | 23/02/2023 |
11 | Jardiance | empagliflozine | 25 mg | comprimé | B/30 | Boehringer Ingelhei Allemagne | E | V | 23/02/2023 |
12 | PROXIDA | Dexmedetomidine | 200 µG/2ml | SOL INJ PR PERF | B/1FL | HIKMA Pharmaceuticals | N | 02/03/2023 | |
13 | ISOSUPRA LIDOSE | ISOTRETINOINE | 8 Mg | Gélule | B/30 | SMB SA | I | N | 07/03/2023 |
14 | TARKA | TRANDOLAPRIL+VERAPAMIL | 180mg /2 mg | COMP LP | B/28 | ABBOTT GmbH & Co.KG | E | N | 07/03/2023 |
15 | TARKA FORTE | TRANDOLAPRIL+VERAPAMIL | 240 mg /4 mg | COMP LP | B/28 | ABBOTT GmbH & Co.KG | E | N | 07/03/2023 |
* Produits à évaluer pour la première fois au Comité Technique
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de la demande | DATE RE |
1 | TRANXENE | CLORAZEPATE DIPOTASSIQUE | 20 MG | PDRE PR PREP INJ | SANOFI AVENTIS France | I | V | CS 29/12/2020 | |
2 | PENTASA | MESALAZINE | 1 g | SUPPO | B/28 | FERRING GmbH | E | N | 28/11/2022 |
3 | LOXEN | NICARDIPINE | 20 MG | COMP SECABLE | B/30 | CARDIXO | E | T | 13/12/2022 |
4 | ALPHAGAN | TARTRATE DE BRIMONIDE | 2MG/ML | COLLYRE | FL/ML | ABBVIE BV VLOG NETHERLAND | T | 22/12/2022 | |
5 | HEALER CREME | MAFENIDE ACETATE | 8.5% | CREME DERMIQUE | T/15 gr | BEIT JALA Pharmaceutical Co | C | N | 05/01/2023 |
6 | KALINOR - retard P | CHLORURE DE POTASSIUM | 600 mg | GELULLE | B/50 | DESMA GmbH | T | 05/01/2023 | |
7 | IMBRUVICA | IBRUTINIB | 560 mg | COM PEL | B/30 | Janssen-Cilag International N.V | E | N | 05/01/2023 |
8 | IMBRUVICA | IBRUTINIB | 420 mg | COM PEL | B/30 | Janssen-Cilag International N.V | E | N | 05/01/2023 |
9 | IMBRUVICA | IBRUTINIB | 280 mg | COM PEL | B/30 | Janssen-Cilag International N.V | E | N | 05/01/2023 |
10 | IMBRUVICA | IBRUTINIB | 140 mg | COM PEL | B/30 | Janssen-Cilag International N.V | E | N | 05/01/2023 |
11 | VENCLYXTO | VENETOCLAX | 10 mg | COM PEL | B/7 | ABBVIE DEUTSCHLAND GmbH & Co,KG | V | CS 10/01/2023 | |
12 | VENCLYXTO | VENETOCLAX | 50 mg | COM PEL | B/7 | ABBVIE DEUTSCHLAND GmbH & Co,KG | V | CS 10/01/2023 | |
13 | VENCLYXTO | VENETOCLAX | 100 mg | COM PEL | B/7 | ABBVIE DEUTSCHLAND GmbH & Co,KG | V | CS 10/01/2023 | |
14 | VENCLYXTO | VENETOCLAX | 100 mg | COM PEL | B/14 | ABBVIE DEUTSCHLAND GmbH & Co,KG | V | CS 10/01/2023 | |
15 | VENCLYXTO | VENETOCLAX | 100 mg | COM PEL | B/112 | ABBVIE DEUTSCHLAND GmbH & Co,KG | V | CS 10/01/2023 | |
16 | JAKAVI | RUXOLITINIB | 15 mg | COMPRIME | B/56 | NOVARTIS PHARMA SCHWEIZ AG | E | V | CS 10/01/2023 |
17 | JAKAVI | RUXOLITINIB | 20 mg | COMPRIME | B/56 | NOVARTIS PHARMA SCHWEIZ AG | E | V | CS 10/01/2023 |
18 | JAKAVI | RUXOLITINIB | 5 mg | COMPRIME | B/56 | NOVARTIS PHARMA SCHWEIZ AG | E | V | CS 10/01/2023 |
19 | INTRATECT | IMMUNOGLOBULINE HUMAINE POLYVALENTE | 10G/200ML | SOL INJ PR PRF | FL/200 ML | BIOTEST PHARMA GMBH | E | V | CS 10/01/2023 |
20 | INTRATECT | IMMUNOGLOBULINE HUMAINE POLYVALENTE | 5G/50ML | SOL INJ PR PRF | FL/50 ML | BIOTEST PHARMA GMBH | E | V | CS 10/01/2023 |
21 | INTRATECT | 10G/10ML | SOL INJ PR PRF | FL/100 ML | BIOTEST PHARMA GMBH | E | V | CS 10/01/2023 | |
22 | SINGULAIR | MONTELUKAST | 4 MG | GRANULES | B/28 | ORGANON BV | T | 18/01/2023 | |
23 | Pemzek | Candesartan | 8 mg | comprimé | B/28 | ASTRA ZENECA SUISSE | E | T | CS 31/01/2023 |
24 | Pemzek | Candesartan | 16 mg | comprimé | B/28 | ASTRA ZENECA SUISSE | E | T | CS 31/01/2023 |
25 | Pemzek PLUS | Candesartan | 8 mg/12.5 MG | comprimé | B/28 | ASTRA ZENECA SUISSE | E | V | CS 31/01/2023 |
26 | Pemzek PLUS | Candesartan+Hydrochlorothiazide | 16 mg/12.5 MG | comprimé | B/28 | ASTRA ZENECA SUISSE | E | V | CS 31/01/2023 |
27 | Jardiance | empagliflozine | 10 mg | comprimé | B/30 | Boehringer Ingelhei Allemagne | E | V | CS 31/01/2023 |
28 | Jardiance | empagliflozine | 25 mg | comprimé | B/30 | Boehringer Ingelhei Allemagne | E | V | CS 31/01/2023 |
29 | ROPIVACAINE KABI | ROPIVACAINE | 5 mg/ml, | solution injectable en ampoule. | B/5 | FRESINUS KABI | E | V | CS 31/01/2023 |
30 | ROPIVACAINE KABI | ROPIVACAINE | 7,5 mg/ml, | solution injectable en ampoule. | B/5 | FRESINUS KABI | E | V | CS 31/01/2023 |
31 | HALAVEN | MESILATE D'ERIBULINE | 0.44 mg/ml | SOL INJ | Fl/2ml | Eisai Europe Limited | V | N | 08/02/2023 |
32 | PYLERA | BISMUTH +METRONIDAZOLE+TETRACYCLINE | 140mg/125mg/125mg | GELULLE | B/120 Gélule | Allergan Sales LLC | E | T | 08/02/2023 |
33 | ENSPRYNG | SATRALIZUMAB | 120 mg/1 ml | SERINGUE | B/1 | Roche Pharma (Schweiz) AG | N | 14/02/2023 | |
34 | RIXATHON | RITUXIMAB | 100 mg | SOL A DIL PR PRF | B/2 FL/10ml | SANDOZ GmbH | V | N | 14/02/2023 |
35 | RIXATHON | RITUXIMAB | 500 mg | SOL A DIL PR PRF | B/2 FL/50ml | SANDOZ GmbH | V | N | 14/02/2023 |
36 | ERLOTINIB MYLAN | ERLOTINIB | 100 mg | COMPRIME | B/30 | MYLAN France | E | N | 22/03/2023 |
37 | ERLOTINIB MYLAN | ERLOTINIB | 150 mg | COMPRIME | B/30 | MYLAN France | E | N | 22/03/2023 |
38 | ZINNAT | CEFUROXIME | 125 MG | COMP PEL | B/14 | Sandoz Pharmaceuticals d.d | T | 04/10/2023 | |
39 | ZINNAT | CEFUROXIME | 125 MG | FLACON | F/70 ML | Sandoz Pharmaceuticals d.d | T | 04/10/2023 | |
40 | ELPIDA | DASATINIB | 20 mg | COMPRIME | B/60 | HIKMA Pharmaceuticals | N | 04/11/2023 | |
41 | ELPIDA | DASATINIB | 50 mg | COMPRIME | B/60 | HIKMA Pharmaceuticals | N | 04/11/2023 | |
42 | ELPIDA | DASATINIB | 140 mg | COMPRIME | B/60 | HIKMA Pharmaceuticals | N | 04/11/2023 | |
43 | ELPIDA | DASATINIB | 70 mg | COMPRIME | B/60 | HIKMA Pharmaceuticals | N | 04/11/2023 | |
44 | RUCORON | ROCURONIUM BROMURE | 50 MG/ 5ML | SOL INJ | B/10 | HIKMA Pharmaceuticals | N | 04/11/2023 | |
45 | PEMITRA | PEMETREXED | 500 mg | PDRE PR PREP INJ | B/1 | HIKMA Pharmaceuticals | N | 04/11/2023 | |
46 | PMS-BORTEZOMIB | BORTEZOMIB | 3.5 mg | PDRE PR PREP INJ | B/1 fl | PHARMASCIENCE INC CANADA | V | N | 04/11/2023 |
47 | ERIVEDGE | VISMODEGIB | 150 mg | GELULLE | B/28 | Roche Pharma (Schweiz) AG | N | 04/11/2023 | |
48 | ERLEADA | APALUTAMIDE | 60 mg | COMP PEL | B/112 | Janssen-Cilag International N.V | N | 04/11/2023 |